The Efficacy of L-cysteine in Prevention of Headache Attacks in Migraine Patients

Conditions Phase Intervention Type
N/A
Drug
Acetium
Placebo

Eligibility

Ages Eligible for Study
18 years to 65 years
Genders Eligible for Study
Both

Keywords

Migraine and Aura

Sponsors

Other
The Finnish Funding Agency for Technology and Innovation (TEKES)
Industry
Biohit Oyj

Inclusion Criteria

- 18-65 years male/female

- subjects should report migraine attacks with the frequency of 2-8 times per month, and
with less than 15 migraine days (NMD) per month. To be calculated as a separate
attack, there should be at least 48h of freedom from headache between the two attacks
of migraine.

- migraine with or without aura has been present for at least 1 year prior to entering
into the study

- subjects to be enrolled should report the onset of their migraine before 50 years of
age

Exclusion Criteria

- patients who meet the International Classification of Headache Disorders II criteria
for medication overuse

- patients who have taken anti-psychotics or anti-depressant medications during the
previous 3 months

- patients who abuse alcohol or other drugs

- patients resistant to all acute migraine drugs optimally prescribed

- potentially fertile and sexually active women who do not practise contraception

- other acute or chronic pain disorders

- severe psychiatric disease

- infection

- malignancy

- short life expectancy

- cardiovascular disease

- cerebrovascular disease

- uncontrolled hypertension

- degenerative central nervous system diseases

- pregnant and lactating women

- regular users of Acetium capsules for other indications

- persons suffering from renal dysfunction or cystinuria

Detailed Description

The purpose of this study is to validate the novel hypothesis that daily use of L-cysteine (Acetium® capsules) is an effective means to decrease the frequency of (or completely abort) the headache attacks in migraine patients.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT02315833

Locations

  • Terveystalo, Kamppi
    Helsinki, Finland

    Status: Recruiting

  • Terveystalo, Jyväskylä
    Jyväskylä, Finland

    Status: Recruiting

  • Terveystalo, Oulu
    Oulu, Finland

    Status: Recruiting

  • Terveystalo, Turku
    Turku, Finland

    Status: Recruiting

  • Lääkärikeskus Aava, Helsingin Päänsärkykeskus Oy
    Helsinki, Finland

    Status: Recruiting

  • Confido Privat Medical Clinic
    Tallinn, Estonia

    Status: Recruiting

    Contact info Marko Ölluk, MD
    00372 505 3420
    Toomas Toomsoo, PhD
    00372 522 8332
See 1 more locations